MedTrace Logo

WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test

NCT01537003 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2013-07-08

No results posted yet for this study

Summary

The purpose of this trial is to determine if wounds with elevated protease activity (EPA) treated with targeted interventions such as protease modulating therapies can improve clinical and economic outcomes.

Multi-centre VLU study to investigate efficacy of WOUNDCHEK™ on EPA wounds

Conditions

  • Venus Leg Ulcers

Interventions

DEVICE

Promogran

Promogran is a collagen/ORC dressing which modulates the wound environment

DEVICE

Coban 2 layer

Compression bandage

Sponsors & Collaborators

  • Systagenix Wound Management

    lead INDUSTRY

Principal Investigators

  • Keith Harding, Prof · Cardiff University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-10-31
Completion
2014-01-31

Countries

  • United States
  • Germany
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01537003 on ClinicalTrials.gov